

STENOCARE A/S

NASDAQ FIRST NORTH GROWTH MARKET, DENMARK

TICKER: STENO

New Product: More choice for treatment of Swedish patients with medical cannabis oil

STENOCARE A/S (“STENOCARE”) and Emerald Health Therapeutics Inc (“Emerald”) hereby announces that the first product shipment and delivery of THC-CBD Balanced medical cannabis oil has been completed on February 12, 2021 to Sweden.

STENOCARE announced on September 8, that medical cannabis oil from their supplier, Emerald, had been accepted for treatment of Swedish patients. In December 2020, the first THC oil products were delivered, and now the first THC-CBD oil products have been delivered to Sweden. With these two products available for treatment, there is more choice for doctors and patients when considering medical cannabis as a supplement to conventional treatment protocols.

In Sweden, several patients diagnosed with chronic nervous system pain, spasms and nausea from chemotherapy have via their doctor applied for a prescription for treatment with THC-CBD medical cannabis oil.

STENOCARE is a leading supplier of premium prescription-based medical cannabis products for patients’ treatment to help them improve quality of life, and for Sweden their Canadian supplier of high-quality medical cannabis products, Emerald, will manufacture and deliver their medical cannabis oil products.

Niels V. Olsen, anesthesiologist, D.M.Sc., at “Smärt och Psykiatri Centrum Malmö” is commenting:

“We have been applying conventional treatment protocols to patients with neuropathic pain and find it relevant to supplement with medical cannabis. We will test how medical cannabis oil can help reduce pain, spasm and enable better mobility for patients with severe chronic pain related to cancer or nerve injuries”

Thomas Skovlund Schnegelsberg, CEO of STEOCARE is commenting:

“With this second type of medical cannabis oil to Sweden there is more choice to doctors and patients. Now they both have a high-THC oil and a balanced THC-CBD oil product available for supplemental treatment”

For additional information regarding STENOCARE, please contact:

Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com

STENOCARE’s Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: info@keswickglobal.com

About STENOCARE A/S

STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.

www.stenocare.se

www.stenocare.com